• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Vincent Brichard - Articles and news items

GlaxoSmithKline logo

Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer

Industry news / 2 April 2014 / GlaxoSmithKline

GlaxoSmithKline plc announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients…

GlaxoSmithKline logo

Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial

Industry news / 20 March 2014 / GlaxoSmithKline

GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population…

GlaxoSmithKline logo

The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial

Industry news, News / 5 September 2013 / GlaxoSmithKline

In line with the Independent Data Monitoring Committee’s unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +